Open access
Open access
Powered by Google Translator Translator

RCT: Ravidasvir plus sofosbuvir are effective and well tolerated in patients with chronic HCV infection, with potential as an affordable treatment for these patients

18 Apr, 2021 | 21:19h | UTC

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial – The Lancet Gastroenterology & Hepatology


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.